Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript

Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript

Seeking Alpha • 7 hours ago

Iovance Biotherapeutics Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates

SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported fourth quarter and full year 2025 financial results, business achievements and corporate updates.

GlobeNewsWire • 13 hours ago

Iovance Biotherapeutics Explodes Over 20% — Early Trial Data Sparks Investor Frenzy

Iovance Biotherapeutics (NASDAQ: IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas.

Benzinga • 6 hours ago

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.

Zacks Investment Research • 10 hours ago

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy.

GlobeNewsWire • 13 hours ago

Iovance Biotherapeutics: Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)

Iovance Biotherapeutics demonstrates improved Q4 results, with $87M revenue and a 50% gross margin (ex-D&A), but remains high-risk/high-reward. AMTAGVI drives IOVA's prospects, with a modeled $1.6B peak sales and first profit expected in 2028, yet manufacturing and adoption remain challenges. Their cash runway extends into Q3 2027, but dilution risk is material as AMTAGVI is unlikely to generate cash before then; ex-U.S. partnerships are a potential solution.

Seeking Alpha • 5 hours ago

IOVA vs. RIGL: Which Small-Cap Biotech Has More Upside Potential?

Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products.

Zacks Investment Research • 10 hours ago

1 Nearly Unknown Biotech Stock Set To Go Parabolic If Its Pipeline Hits

This biotech stock won approval for a cancer treatment a couple of years ago. That treatment is starting to generate revenue growth.

The Motley Fool • Feb 23, 2026

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on February 19, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance's common stock to two new, non-executive employees.

GlobeNewsWire • Feb 20, 2026

Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026

SAN CARLOS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast on Tuesday, February 24, 2026 at 8:30 a.m. ET to report its fourth quarter and full year 2025 financial results and corporate updates.

GlobeNewsWire • Feb 11, 2026